Patient P-02068
Therapy response
Improving
Tolerance
Deteriorating
GI state
Favorable
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
15%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 26 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 30 NP-02 recommended — Dietary Support Protocol NP-02
- Day 31 Patient accepted — Started NP-02 in the companion
- Day 41 GI symptom burden −12% vs expected — Dietary Support Protocol NP-02
- Day 47 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 26.
Primary contributors, last 14 days
- Toxicity+7
- GI instability-3
- Nutritional resilience+3
What helped?
- Dietary Support Protocol NP-02Day 30Result: symptom burden −12%
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable37 min
improving · +2.4 vs previous 14 d
Sleep duration
Wearable8.9 h
stable · +0.2 vs previous 14 d
Energy level
Daily log8.3/10
improving · +0.8 vs previous 14 d
Steps
Wearable4,297
improving · +249 vs previous 14 d
GI burden
Companion6.6/100
improving · -7.2 vs previous 14 d
Adherence
Companion92.5 %
stable · +1.8 vs previous 14 d
Sleep quality
Wearable89.4/100
improving · +3.4 vs previous 14 d
Glucose, CGM daily mean
CGM120 mg/dL
stable · -1.4 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards restoration · 100 from the failing basin, 14 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -7.1 next day on high-intake days · n 24
Would not help
- Nothing clearly counter-productive in the record.
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-7.1supporter · 95%
- Simple carbohydrates+1.2no signal · 18%
- Caffeine-0.9no signal · 15%
- Histamine load-0.8no signal · 15%
- Alcohol+0.8no signal · 15%
- Ultra-processed food-0.4no signal · 15%
- Dietary fat load+0.1no signal · 15%
- Insoluble fibre-0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↓20
- MicrobiomeBacteroides fragilis expansion
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
Microbiome
Shannon diversity 4.2 · butyrate capacity 79/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 65 ms
- Sleep
- 8.3 h
- Steps
- 4,060
- Resting HR
- 71 bpm
Daily log: GI score 7, nutritional resilience 73, adherence 93.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02337 | 38% | S18 | DT-01 | no change | 100 |
| P-02249 | 36% | S09 | DT-01 | improved | 100 |
| P-02189 | 42% | S17 | — | — | 96 |
| P-02640 | 37% | S03 | — | — | 96 |
| P-02242 | 37% | S20 | — | — | 95 |
| P-02013 | 36% | S14 | BR-03 | no change | 94 |
| P-02104 | 36% | S15 | — | — | 94 |
| P-02450 | 39% | S12 | NP-02 | improved | 92 |
| P-02277 | 42% | S05 | AD-05 | improved | 92 |
| P-02304 | 31% | S15 | — | — | 92 |
| P-02653 | 49% | S14 | — | — | 91 |
| P-02689 | 36% | S13 | — | — | 91 |